Bookbuilding IPO | ₹139 Cr | Listing at BSE, NSE | Fri, Jun 5, 2026 - Tue, Jun 9, 2026 O
Hexagon Nutrition IPO is a book build issue of ₹138.87 crores. The issue is entirely an offer for sale of 3.09 crore shares of ₹138.87 crore.
Hexagon Nutrition IPO bidding opened for subscription on Jun 5, 2026 and will close on Jun 9, 2026. The allotment for the Hexagon Nutrition IPO is expected to be finalized on Jun 10, 2026. Hexagon Nutrition IPO will list on NSE and BSE with a tentative listing date fixed as Jun 12, 2026.
Hexagon Nutrition IPO is set issue price band at ₹42 to ₹45 per share. The lot size for an application is 333 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,985 (333 shares) (based on upper price). The lot size investment for sNII is 14 lots (4,662 shares), amounting to ₹2,09,790, and for bNII, it is 67 lots (22,311 shares), amounting to ₹10,03,995.
Cumulative Capital Pvt.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Hexagon Nutrition IPO RHP for detailed Information.
IPO Open
Fri, Jun 5, 2026
IPO Close
Tue, Jun 9, 2026
Price Band
₹42 to ₹45
Market Cap (Pre-IPO)
₹553.13 Cr
| IPO Date | 5 to 9 Jun, 2026 |
| Listing Date | Fri, Jun 12, 2026T |
| Face Value | ₹1 per share |
| Price Band | ₹42 to ₹45 |
| Lot Size | 333 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 3,08,59,704 shares (agg. up to ₹139 Cr) |
| Offer for Sale | 3,08,59,704 shares of ₹1 (agg. up to ₹139 Cr) |
| Share Holding Pre Issue | 12,29,18,109 shares |
| Share Holding Post Issue | 12,29,18,109 shares |
Hexagon Nutrition IPO comprises a total issue size of 3,08,59,704 shares. Out of which, 1,54,29,852 (50.00%) are allocated to QIB, 46,28,956 (15.00%) allocated to NII 1,08,00,896 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Total Issue | Max Allottees |
|---|---|---|---|
| QIB Shares Offered | 1,54,29,852 | 50.00% | NA |
| − Anchor Investor Shares Offered | 92,57,696 | 30.00% | NA |
| − QIB (Ex. Anchor) Shares Offered | 61,72,156 | 20.00% | NA |
| NII (HNI) Shares Offered | 46,28,956 | 15.00% | NA |
| − bNII > ₹10L | 30,85,970 | 10.00% | 661 |
| − sNII < ₹10L | 15,42,985 | 5.00% | 330 |
| Retail Shares Offered | 1,08,00,896 | 35.00% | 32,435 |
| Total Shares Offered | 3,08,59,704 | 100.00% |
Investors can bid for a minimum of 333 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 333 | ₹14,985 |
| Retail (Max) | 13 | 4,329 | ₹1,94,805 |
| S-HNI (Min) | 14 | 4,662 | ₹2,09,790 |
| S-HNI (Max) | 66 | 21,978 | ₹9,89,010 |
| B-HNI (Min) | 67 | 22,311 | ₹10,03,995 |
Hexagon Nutrition IPO raises ₹41.66 crore from anchor investors. Hexagon Nutrition IPO Anchor bid date is June 4, 2026.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Jun 4, 2026 |
| Shares Offered | 92,57,696 |
| Anchor Portion (₹ Cr.) | 41.66 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jul 10, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Sep 8, 2026 |
Incorporated in 1993, Hexagon Nutrition Ltd. is a research-driven nutrition company. It is engaged in developing and manufacturing products across micronutrient premixes, branded wellness and clinical nutrition, therapeutic formulations, and ready-to-use foods.
The company operates three manufacturing facilities in India, located at Nasik (Maharashtra), Chennai (Tamil Nadu), and Thoothukudi (Tamil Nadu), along with an international unit in Tashkent, Uzbekistan. Two Indian facilities are situated in SEZ zones at Chennai and Thoothukudi, providing strategic advantages such as proximity to ports and duty-free imports.
Its product portfolio is classified into three segments:
Hexagon Nutrition has a PAN-India omnichannel distribution network covering retail pharmacies, hospital networks, e-commerce platforms, online pharmacies, and its own branded websites including Pentasure, Obesigo, Pediagold, and Nutrone. For domestic distribution, it works with over 358 distributors across India, including 8 with multi-state presence.
The company has established overseas offices in South Africa, Uzbekistan, and Hong Kong to support international operations. Its products have been exported to more than 75 countries across Asia, Africa, Europe, and South America between fiscals 2023 and 2025.
Hexagon Nutrition maintains two dedicated in-house R&D facilities at Nasik and Chennai, supported by a team of 12 qualified professionals. As of March 31, 2026, the company employed 527 people.
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 327.60 | 261.36 | 250.54 | 288.90 |
| Total Income | 275.57 | 331.29 | 304.62 | 281.65 |
| Profit After Tax | 27.03 | 24.38 | 12.21 | 5.82 |
| EBITDA | 37.55 | 40.07 | 24.88 | 17.17 |
| NET Worth | 223.05 | 195.60 | 176.29 | 163.84 |
| Reserves and Surplus | 210.92 | 183.89 | 164.51 | 152.30 |
| Total Borrowing | 39.79 | 26.60 | 36.89 | 51.87 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | ₹405.70 | +3.49% | ₹545.20 (-0.33%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | ₹1,438.40 | +35.44% | ₹1,725.00 (+1.22%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.68 Cr | ₹485 | ₹628.20 | +29.53% | ₹1,202.50 (-7.29%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | ₹141.75 | +12.50% | ₹133.49 (-0.26%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | ₹91.73 | +0.80% | ₹13.98 (-1.27%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | ₹115.80 | -16.69% | ₹122.50 (+4.97%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | ₹56.77 | +32.02% | ₹45.25 (+5.33%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | ₹125.90 | +1.53% | ₹216.05 (-1.84%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | ₹191.20 | +48.22% | ₹268.50 (+2.68%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | ₹180.70 | +33.85% | ₹239.50 (-3.80%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | ₹141.00 | +10.16% | ₹112.00 (+2.75%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | ₹84.84 | +21.20% | ₹229.65 (+2.00%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | ₹124.95 | +1.59% | ₹68.66 (-5.96%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | ₹126.20 | +31.46% | ₹239.00 (-2.73%) |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 13.02% | 10.47% |
| ROCE | 14.82% | 17.06% |
| Debt/Equity | 0.18 | 0.14 |
| RoNW | 12.12% | 12.46% |
| PAT Margin | 9.81% | 7.36% |
| EBITDA Margin | 14.03% | 12.33% |
| Price to Book Value | 2.48 | 2.83 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 1.98 | 2.93 |
| P/E (x) | 22.69 | 15.35 |
| Promoter Holding | 89.41% | 64.29% |
| Market Cap | ₹553.13 Cr. |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Managers’ fees and commission (including underwriting commission), brokerage and selling commission, as applicable | |
| 2 | Brokerage, commission/processing fee for SCSBs, Sponsor Bank and Bankers to the Offer. Brokerage, and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | |
| 3 | Fees payable to the Registrar to the Offer | |
| 4 | Others: Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | |
| 5 | Printing and distribution of issue stationery | |
| 6 | Advertising and marketing expenses | |
| 7 | Fees payable to legal counsels | |
| 8 | Fees payable to statutory auditors for the Offer | |
| 9 | Fees payable to other advisors to the Offer | |
| 10 | Miscellaneous |
Lead Manager Reports
Hexagon Nutrition IPO is a main-board IPO of 3,08,59,704 equity shares of the face value of ₹1 aggregating up to ₹139 Crores. The issue is priced at ₹42 to ₹45. The minimum order quantity is 333.
The IPO opens on Fri, Jun 5, 2026, and closes on Tue, Jun 9, 2026.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Hexagon Nutrition IPO using UPI as a payment gateway. Zerodha customers can apply in Hexagon Nutrition IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Hexagon Nutrition IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Hexagon Nutrition IPO opens on Fri, Jun 5, 2026 and closes on Tue, Jun 9, 2026.
Hexagon Nutrition IPO lot size is 333, and the minimum amount required for application is ₹14,985.
You can apply in Hexagon Nutrition IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Hexagon Nutrition IPO will be done on Wednesday, June 10, 2026, and the allotted shares will be credited to your demat account by Thu, Jun 11, 2026. Check the Hexagon Nutrition IPO allotment status.
The Hexagon Nutrition IPO listing date is not yet announced. The tentative date of listing is Fri, Jun 12, 2026.
